Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study

    Access Status
    Open access via publisher
    Authors
    Lew, J.
    St John, D.
    Xu, X.
    Greuter, M.
    Caruana, M.
    Cenin, Dayna
    He, E.
    Saville, M.
    Grogan, P.
    Coupé, V.
    Canfell, K.
    Date
    2017
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Lew, J. and St John, D. and Xu, X. and Greuter, M. and Caruana, M. and Cenin, D. and He, E. et al. 2017. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study. The Lancet Public Health. 2 (7): pp. e331-e340.
    Source Title
    The Lancet Public Health
    DOI
    10.1016/S2468-2667(17)30105-6
    ISSN
    2468-2667
    School
    Health Sciences Research and Graduate Studies
    URI
    http://hdl.handle.net/20.500.11937/55185
    Collection
    • Curtin Research Publications
    Abstract

    © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Background No assessment of the National Bowel Screening Program (NBCSP) in Australia, which considers all downstream benefits, costs, and harms, has been done. We aimed to use a comprehensive natural history model and the most recent information about cancer treatment costs to estimate long-term benefits, costs, and harms of the NBCSP (2 yearly immunochemical faecal occult blood testing screening at age 50–74 years) and evaluate the incremental effect of improved screening participation under different scenarios. Methods In this modelling study, a microsimulation model, Policy1-Bowel, which simulates the development of colorectal cancer via both the conventional adenoma-carcinoma and serrated pathways was used to simulate the NBCSP in 2006–40, taking into account the gradual rollout of NBCSP in 2006–20. The base-case scenario assumed 40% screening participation (currently observed behaviour) and two alternative scenarios assuming 50% and 60% participation by 2020 were modelled. Aggregate year-by-year screening, diagnosis, treatment and surveillance-related costs, resource utilisation (number of screening tests and colonoscopies), and health outcomes (incident colorectal cancer cases and colorectal cancer deaths) were estimated, as was the cost-effectiveness of the NBCSP. Findings With current levels of participation (40%), the NBCSP is expected to prevent 92 200 cancer cases and 59 000 deaths over the period 2015–40; an additional 24 300 and 37 300 cases and 16 800 and 24 800 deaths would be prevented if participation was increased to 50% and 60%, respectively. In 2020, an estimated 101 000 programme-related colonoscopies will be done, associated with about 270 adverse events; an additional 32 500 and 49 800 colonoscopies and 88 and 134 adverse events would occur if participation was increased to 50% and 60%, respectively. The overall number needed to screen (NNS) is 647–788 per death prevented, with 52–59 colonoscopies per death prevented. The programme is cost-effective due to the cancer treatment costs averted (cost-effectiveness ratio compared with no screening at current participation, AUS$3014 [95% uncertainty interval 1807–5583] per life-year saved) in the cost-effectiveness analysis. In the budget impact analysis, reduced annual expenditure on colorectal cancer control is expected by 2030, with expenditure reduced by a cumulative AUS$1·7 billion, AUS$2·0 billion, and AUS$2·1 billion (2015 prices) between 2030 and 2040, at participation rates of 40%, 50%, and 60%, respectively. Interpretation The NBCSP has potential to save 83 800 lives over the period 2015–40 if coverage rates can be increased to 60%. By contrast, the associated harms, although an important consideration, are at a smaller magnitude at the population level. The programme is highly cost-effective and within a decade of full roll-out, there will be reduced annual health systems expenditure on colorectal cancer control due to the impact of screening. Funding Australia Postgraduate Award PhD Scholarship, Translational Cancer Research Network Top-up scholarship (supported by Cancer Institute NSW) and Cancer Council NSW.

    Related items

    Showing items related by title, author, creator and subject.

    • Optimising the expansion of the National Bowel Cancer Screening Program
      Cenin, D.; St John, D J.; Ledger, M.; Slevin, Terry; Lansdorp-Vogelaar, I. (2014)
      Objectives: To estimate the impact of various expansion scenarios of the National Bowel Cancer Screening Program (NBCSP) on the number of bowel cancer deaths prevented; and to investigate the impact of the expansion ...
    • Cost-Effectiveness of an Advance Notification Letter to Increase Colorectal Cancer Screening
      Cronin, P.; Goodall, S.; O'Keefe, C.; Lockett, T.; Norman, Richard; Church, J. (2013)
      Objectives: The aim of this study is to evaluate the cost-effectiveness of a patient-direct mailed advance notification letter on participants of a National Bowel Cancer Screening Program (NBCSP) in Australia, which was ...
    • Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: Study design
      Rigter, L.; Spaander, M.; Moons, L.; Bisseling, T.; Aleman, B.; de Boer, J.; Lugtenburg, P.; Janus, C.; Petersen, E.; Roesink, J.; Raemaekers, J.; van der Maazen, R.; Cats, A.; Bleiker, E.; Snaebjornsson, P.; Carvalho, B.; Lansdorp_Vogelaar, Iris; Józwiak, K.; te Riele, H.; Meijer, G.; van Leeuwen, F.; van Leerdam, M. (2017)
      Background: Second primary malignancies are a major cause of excess morbidity and mortality in cancer survivors. Hodgkin lymphoma survivors who were treated with infradiaphragmatic radiotherapy and/or high-dose procarbazine ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.